TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8563662
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CB)
Study: 10224730
Drug: Psychodynamic-interpersonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic-interpersonal therapy (PI)
Study: 8563662
Drug: Sixteen sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sixteen sessions of therapy
Study: 30926189
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine (0.75 mg/kg)
Study: 30926189
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo (saline solution)
Study: 21252259
Drug: Endotoxin core
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Endotoxin core antibody (EndoCAb)
Study: 19503012
Drug: Prednisolone 60
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 60 mg daily for 5 days, then tapering for 5 days plus placebo
Study: 19503012
Drug: Valacyclovir 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 1,000 mg 3 times daily for 7 days plus placebo
Study: 12544447
Drug: Low salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low salt (7.8 +/- 0.9 to 11.2 +/- 1.4 ml/min per 100 ml)
Study: 12544447
Drug: High salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: High salt (8.5 +/- 1.2 to 10.4 +/- 1.3 ml/min per 100 ml)
Study: 10871469
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist therapy
Study: 9062479
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose T3 treatment for 63 days
Study: 9439537
Drug: T3 treatment
Normalized name: T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T3 treatment
Study: 3534021
Drug: Topical tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tretinoin (retinoic acid and Retin-A) delivered by cervical cap and inert collagen sponge system
Study: 25244700
Drug: Drug-eluting balloons
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting balloons (DEB)
Study: 20585000
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day modafinil
Study: 10100363
Drug: DDAVP spray
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DDAVP spray at 20 mcg/day for 6 weeks
Study: 10100363
Drug: DDAVP spray
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DDAVP spray at 30 mcg/day for 6 weeks
Study: 10100363
Drug: DDAVP spray
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DDAVP spray at 20 mcg/day for 2 weeks, then 30 mcg/day for 2 weeks after washout
Study: 10100363
Drug: DDAVP spray
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DDAVP spray at 30 mcg/day for 2 weeks, then 20 mcg/day for 2 weeks after washout
Study: 10100363
Drug: DDAVP spray
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DDAVP spray at doses ranging from 20 to 40 mcg/day
Study: 8682086
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus IFN
Study: 8682086
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus thymomodulin
Study: 8682086
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus IFN and thymomodulin
Study: 2351902
Drug: Conventional infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional infusion
Study: 31973934
Drug: Coolant spray
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coolant spray (Cryos ®Spray, Phyto Performance, Italy)
Study: 12188410
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline spray (placebo)
Study: 31973934
Drug: Coolant spray
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coolant spray
Study: 20958851
Drug: Group Drug
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Drug Counseling (GDC)
Study: 22465116
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive containing 20 mcg of ethinylestradiol (EE) and 3 mg of drospirenone (DRSP)
Study: 17963466
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propofol and ketamine
Study: 17963466
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of ketamine added to propofol
Study: 16131580
Drug: L-T4 (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-T4 (titrated to maintain low TSH)
Study: 16131580
Drug: L-T4 (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-T4 (titrated to restore euthyroidism)
Study: 11853247
Drug: Resin-sealant (Concise)
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin-sealant (Concise) with acid etch and tooth preparation
Study: 11853247
Drug: Compomer restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compomer restorative material (F2000) with acid etch, bonding agent, and tooth preparation
Study: 11853247
Drug: Compomer restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compomer restorative material (F2000) with bonding agent and no tooth preparation
Study: 11853247
Drug: Compomer restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compomer restorative material (F2000) with bonding agent and tooth preparation
Study: 11853247
Drug: Compomer restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compomer restorative material (F2000) with bonding agent and without enameloplasty
Study: 11853247
Drug: Compomer with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compomer with acid etching and bonding agent
Study: 8950882
Drug: Naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50 mg per day
Study: 7039533
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (30 to 60 mg orally for six days before operation)
Study: 28835059
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (hydromorphone hydrochloride 1 μg·kg(‐1)·h(‐1) + flurbiprofen axetil 200 mg)
Study: 28835059
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (hydromorphone hydrochloride 2 μg·kg(‐1)·h(‐1))
Study: 28835059
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (hydromorphone hydrochloride 1 μg·kg(‐1)·h(‐1))
Study: 24770960
Drug: Alcohol SPN
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol SPN (1 ml of absolute alcohol injected under CT guidance)
Study: 7587855
Drug: AC137 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AC137 infusion (50 micrograms/h) during a standardized Sustacal meal (350 kcal) challenge.
Study: 7587855
Drug: AC137 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AC137 infusion (steady-state concentrations of 234 +/- 16 pmol/l) during an intravenous glucose load (300 mg/kg).
Study: 2210097
Drug: 80 mM
Normalized name: Koromex Coil Diaphragm 80 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mM glucose-sodium chloride solution
Study: 2210097
Drug: Ileal glucose-stimulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ileal glucose-stimulated water absorption
Study: 2210097
Drug: Jejunal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jejunal glucose absorption
Study: 2210097
Drug: Ileal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ileal glucose absorption
Study: 26547414
Drug: LF-0.6 (formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: LF-0.6 (formula with 0.6 g/L bLf)
Study: 26547414
Drug: LF-1.0 (formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: LF-1.0 (formula with 1.0 g/L bLf)
Study: 19276858
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of 19‐norandrostenedione
Study: 15358988
Drug: Reboxetine 4
Normalized name: reboxetine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine 4 mg/day
Study: 9013010
Drug: Lytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lytic therapy followed by heparin and warfarin (group 2)
Study: 9013010
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (heparin and warfarin) (group 1)
Study: 1334103
Drug: Conservative surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative surgery and radiation therapy
Study: 28716351
Drug: Home-based curative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based curative health services provided by trained lady health workers (LHWs) including neonatal bag and mask resuscitation and oral amoxicillin for suspected infections.
Study: 17309383
Drug: Agaricus blazei
Normalized name: AGARICUS BLAZEI WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agaricus blazei Murill (ABM) extract 1500 mg daily for 12 weeks
Study: 9556464
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg of aspirin every other day
Study: 9556464
Drug: Self-selected aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-selected aspirin use after 1988
Study: 3228680
Drug: Caffeine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (7 mg.kg‐1)
Study: 18220486
Drug: pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone 45 mg/day
Study: 26311750
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of DFZ
Study: 26311750
Drug: Daily PRED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily PRED
Study: 26311750
Drug: Daily DFZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily DFZ
Study: 23146816
Drug: Tariquidar (TQD)
Normalized name: Tariquidar
DrugBank: Tariquidar (DB06240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tariquidar (TQD) at 4 mg/kg
Study: 23146816
Drug: Tariquidar (TQD)
Normalized name: Tariquidar
DrugBank: Tariquidar (DB06240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tariquidar (TQD) at 6 mg/kg
Study: 23146816
Drug: Tariquidar (TQD)
Normalized name: Tariquidar
DrugBank: Tariquidar (DB06240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tariquidar (TQD) at 8 mg/kg
Study: 22011689
Drug: Tocilizumab 10
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab 10 mg/kg
Study: 22011689
Drug: Tocilizumab 20
Normalized name: tocilizumab 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 20 mg/kg
Study: 17021768
Drug: Efalizumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab (1 mg/kg once weekly)
Study: 17021768
Drug: Efalizumab (extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab (extended treatment phase)
Study: 17021768
Drug: Efalizumab (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab (long-term treatment phase)
Study: 14735295
Drug: quetiapine 25
Normalized name: quetiapine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: quetiapine 25 mg
Study: 14735295
Drug: quetiapine 100
Normalized name: quetiapine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: quetiapine 100 mg
Study: 11103798
Drug: ONYX-015 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONYX-015 (1 x 10^10 pfu via intratumoral injection for 5 days during week 1 of each 3-week cycle)
Study: 11103798
Drug: ONYX-015 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONYX-015 (1 x 10^10 pfu twice a day for 10 days during weeks 1 and 2 of each 3-week cycle)
Study: 9197929
Drug: Selenium (Se)
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (Se) administration at 4000 micrograms per day from 4 days before to 4 days after chemotherapy in group A.
Study: 9197929
Drug: Selenium (Se)
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (Se) administration in group A.
Study: 9197929
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Se administration in first cycle, Se in second cycle).
Study: 2991832
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of conjugated estrogen for 25 days each month
Study: 2991832
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of depo‐medroxyprogesterone acetate intramuscularly every three months
Study: 18812733
Drug: 3% albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% albumin solution (L group, n = 68)
Study: 16815748
Drug: Pramipexole 0.125
Normalized name: pramipexole 0.125 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 0.125 mg
Study: 16815748
Drug: Pramipexole 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 0.50 mg
Study: 10972371
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg twice-weekly subcutaneous injections)
Study: 9117012
Drug: Prednisolone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (20 mg for 2 weeks followed by 10 mg for 4 weeks)
Study: 9032569
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of treatment groups
Study: 10071548
Drug: Alfuzosin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin (12 months treatment)
Study: 10071548
Drug: Alfuzosin (12-18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin (12-18 months treatment)
Study: 3728935
Drug: Intravenous fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluids (2 litres)
Study: 31917122
Drug: SOX (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOX (100 mg/m2 of oxaliplatin on day 1 and 80 mg/m2 of S-1 on days 1-14, every 21 days, 8 cycles)
Study: 31917122
Drug: UFT/LV (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT/LV (300 mg/m2 of UFT and 75 mg/day of LV on days 1-28, every 35 days, 5 cycles)
Study: 27842269
Drug: Intensive Language‐Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive Language‐Action Therapy (ILAT)
Study: 27842269
Drug: Naming Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naming Therapy
Study: 24200249
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy (shavasana with soothing background music) daily for 1 hour for 6 weeks
Study: 23357775
Drug: Tigecycline 100
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tigecycline 100 mg (150 mg followed by 75 mg every 12 h)
Study: 23357775
Drug: Tigecycline 75
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tigecycline 75 mg (200 mg followed by 100 mg every 12 h)
Study: 23357775
Drug: Imipenem/cilastatin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (1 g every 8 h)
Study: 14974909
Drug: Oral oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestrogen (Premarin 1.25 mg) + Norethisterone (2.5 mg)
Study: 14974909
Drug: Transdermal oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oestrogen (Estraderm 100 microg patches twice weekly) + MPA (10 mg)
Study: 14974909
Drug: Transdermal oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oestrogen (Estraderm 100 microg patches twice weekly) + Norethisterone (2.5 mg)
Study: 14974909
Drug: Oral oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestrogen (Premarin 1.25 mg) + MPA (10 mg)
Study: 14974909
Drug: Transdermal oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oestrogen (Estraderm 100 microg patches twice weekly) + CA (5 mg)
Study: 14974909
Drug: Transdermal oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oestrogen (Estraderm 100 microg patches twice weekly) + Dydrogesterone (20 mg)
Study: 14974909
Drug: Oral oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestrogen (Premarin 1.25 mg) + Progestogens (various types)
Study: 14974909
Drug: Transdermal oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oestrogen (Estraderm 100 microg patches twice weekly) + Progestogens (various types)
Study: 14974909
Drug: Oral oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestrogen (Premarin 1.25 mg) + MPA (10 mg) and Norethisterone (2.5 mg)
Study: 12574184
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg/d
Study: 12458987
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (alendronate and estrogen)
Study: 10697060
Drug: Estrogen 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen 0.625 mg/d
Study: 7738622
Drug: 5‐FU 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU 600 mg/m2 plus FA 300 mg/m2 on days 2 to 4 with DP 75 mg orally three times daily on days 1 to 5
Study: 7738622
Drug: 5‐FU 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU 600 mg/m2 plus FA 300 mg/m2 on days 2 to 4 without DP
Study: 1914056
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 0.5% bupivacaine with epinephrine 5 micrograms.ml‐1 (bupivacaine group, n = 10)
Study: 1914056
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml preservative-free saline (placebo group, n = 10)
Study: 7267679
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg LM 5008
Study: 14550686
Drug: IV heroin
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV heroin maintenance treatment
Study: 14550686
Drug: IV methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV methadone maintenance treatment
Study: 8669677
Drug: 5% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% hyperbaric lidocaine with epinephrine (60 mg for arthroscopy or 75 mg for hernia repair)
Study: 8669677
Drug: 2% isobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% isobaric lidocaine without epinephrine (60 mg for arthroscopy or 75 mg for hernia repair)
Study: 8669677
Drug: 0.75% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% hyperbaric bupivacaine without epinephrine (7.5 mg for arthroscopy or 9.0 mg for hernia repair)
Study: 3897560
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg Oltipraz (single dose)
Study: 3897560
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg Oltipraz (split dose)
Study: 27531573
Drug: Tramadol hydrochloride/acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol hydrochloride/acetaminophen combination (TRAM/APAP)
Study: 3157894
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drug (NSAID)
Study: 15688279
Drug: rgp120 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rgp120 vaccine
Study: 8991490
Drug: Dilacor XR
Normalized name: Dilacor XR
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dilacor XR (180 mg d‐1)
Study: 8991490
Drug: Dilacor XR
Normalized name: Dilacor XR
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dilacor XR (540 mg d‐1)
Study: 1318364
Drug: Foscarnet (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet (200 mg/kg continuous infusion prior to 1988 or 60 mg/kg t.i.d. or 90 mg/kg b.i.d. intermittent infusion with saline hyperhydration)
Study: 6147838
Drug: lormetazepam (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: lormetazepam (1.5 mg)
Study: 6353523
Drug: flurazepam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: flurazepam (30 mg)
Study: 11104841
Drug: temazepam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: temazepam (30 mg)
Study: 6147838
Drug: active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: active drug conditions (lormetazepam, flurazepam, temazepam)
Study: 6147838
Drug: active drugs
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: active drugs
Study: 29743078
Drug: MIV‐711 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIV‐711 (single oral doses from 20 to 600 mg in humans; 3‐30 µmol/kg in monkeys)
Study: 29743078
Drug: MIV‐711 (repeat
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIV‐711 (repeat oral dosing)
Study: 21239190
Drug: AS195 (red-vine-leaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS195 (red-vine-leaf extract) 720 mg per day for 12 weeks
Study: 12728086
Drug: 3-component acellular
Normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-component acellular pertussis vaccine administered at birth (group 1)
Study: 12728086
Drug: 3-component acellular
Normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-component acellular pertussis vaccine administered at 3, 5, and 11 months (group 2)